TransMedics Group Financials - Benzinga

TransMedics Group Inc

TMDXNASDAQ

Trade with Public

Trade with Public

$88.34

-1.64-1.82%

Últ. Act.: Sep 8, 1:51 PM

Panorámica general Noticias Previsión de beneficios Eventos Precios objetivoFinanzasSentimiento Propiedad Comparar Opciones Informe de acciones

TransMedics Group Financials

TransMedics Group (TMDX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
TransMedics Group Raises FY2026 Sales Guidance from $727.000M-$757.000M to $737.000M-$757.000M vs $732.700M Est

TransMedics Group (NASDAQ:TMDX) raises FY2026 sales outlook from $727.000 million-$757.000 million to $737.000 million-$757.000 million vs $732.700 million estimate.

Benzinga Newsdesk

PRO
TransMedics Gr Q2 Adj. EPS $0.44 Misses $0.47 Estimate, Sales $189.948M Beat $183.635M Estimate

TransMedics Gr (NASDAQ:TMDX) reported quarterly earnings of $0.44 per share which missed the analyst consensus estimate of $0.47 by 6.38 percent. This is a 52.17 percent decrease over earnings of $0.92 per share from

Benzinga Newsdesk

PRO
TransMedics Group Affirms FY2026 Sales Guidance of $727.000M-$757.000M vs $737.825M Est

TransMedics Group (NASDAQ:TMDX) affirms FY2026 sales outlook from $727.000 million-$757.000 million to $727.000 million-$757.000 million vs $737.825 million estimate.

Benzinga Newsdesk

PRO
TransMedics Gr Q1 Adj. EPS $0.30 Misses $0.61 Estimate, Sales $173.933M Beat $172.636M Estimate

TransMedics Gr (NASDAQ:TMDX) reported quarterly earnings of $0.30 per share which missed the analyst consensus estimate of $0.61 by 50.82 percent. This is a 59.46 percent decrease over earnings of $0.74 per share from

Benzinga Newsdesk

Earnings Scheduled For May 5, 2026

Benzinga Insights

TransMedics Group Earnings Review: Q4 Summary

Benzinga Insights

© 2026 Benzinga | All Rights Reserved